389 related articles for article (PubMed ID: 33709547)
1. Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling.
Saxena N; Beraldi E; Fazli L; Somasekharan SP; Adomat H; Zhang F; Molokwu C; Gleave A; Nappi L; Nguyen K; Brar P; Nikesitch N; Wang Y; Collins C; Sorensen PH; Gleave M
EMBO Mol Med; 2021 May; 13(5):e13427. PubMed ID: 33709547
[TBL] [Abstract][Full Text] [Related]
2. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.
Zoubeidi A; Zardan A; Beraldi E; Fazli L; Sowery R; Rennie P; Nelson C; Gleave M
Cancer Res; 2007 Nov; 67(21):10455-65. PubMed ID: 17974989
[TBL] [Abstract][Full Text] [Related]
3. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.
Karacosta LG; Foster BA; Azabdaftari G; Feliciano DM; Edelman AM
J Biol Chem; 2012 Jul; 287(29):24832-43. PubMed ID: 22654108
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.
Nikesitch N; Beraldi E; Zhang F; Adomat H; Bell R; Suzuki K; Fazli L; Hy Kung S; Wells C; Pinette N; Saxena N; Wang Y; Gleave M
Oncogene; 2023 Mar; 42(10):748-758. PubMed ID: 36611121
[TBL] [Abstract][Full Text] [Related]
5. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
6. Regulation of AR mRNA translation in response to acute AR pathway inhibition.
Somasekharan SP; Saxena N; Zhang F; Beraldi E; Huang JN; Gentle C; Fazli L; Thi M; Sorensen PH; Gleave M
Nucleic Acids Res; 2022 Jan; 50(2):1069-1091. PubMed ID: 34939643
[TBL] [Abstract][Full Text] [Related]
7. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
8. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
9. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
10. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
Shah S; Carriveau WJ; Li J; Campbell SL; Kopinski PK; Lim HW; Daurio N; Trefely S; Won KJ; Wallace DC; Koumenis C; Mancuso A; Wellen KE
Oncotarget; 2016 Jul; 7(28):43713-43730. PubMed ID: 27248322
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
12. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
13. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
Lv S; Song Q; Chen G; Cheng E; Chen W; Cole R; Wu Z; Pascal LE; Wang K; Wipf P; Nelson JB; Wei Q; Huang W; Wang Z
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332287
[TBL] [Abstract][Full Text] [Related]
14. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
15. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
16.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
18. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
20. SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.
Thomas R; Sharifi N
Mol Cancer Ther; 2012 Jan; 11(1):87-97. PubMed ID: 22172488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
